Articles by Paul P. Dobesh, PharmD
Best Practices for Implementing Venous Thromboembolism Prophylaxis Across the Continuum of Care
ByPaul P. Dobesh, PharmD,Tania Ahuja, PharmD,George A. Davis, PharmD,Hugh Fatodu, MBA, RPh,William H. Francis, MBA, RPh,Frank P. Hull, MD,Gary L. Johnson, MD, MS, MBA,Joshua D. Lenchus, DO, BSPharm,Jacqueline Glee Lenoir, PharmD,Claudette McPherson, RN, BSN,Jeffrey Nemeth, PharmD, MPA,Ralph J. Riello III, PharmD The Use of Betrixaban for Extended Prophylaxis of Venous Thromboembolism Events in Hospitalized, High-Risk Patients
ByPaul P. Dobesh, PharmD,Tania Ahuja, PharmD,George A. Davis, PharmD,Hugh Fatodu, MBA, RPh,William H. Francis, MBA, RPh,Frank P. Hull, MD,Gary L. Johnson, MD, MS, MBA,Joshua D. Lenchus, DO, BSPharm,Jacqueline Glee Lenoir, PharmD,Claudette McPherson, RN, BSN,Jeffrey Nemeth, PharmD, MPA,Ralph J. Riello III, PharmD Venous Thromboembolism in Acute Medically Ill Patients: Identifying Unmet Needs and Weighing the Value of Prophylaxis
ByPaul P. Dobesh, PharmD,Tania Ahuja, PharmD,George A. Davis, PharmD,Hugh Fatodu, MBA, RPh,William H. Francis, MBA, RPh,Frank P. Hull, MD,Gary L. Johnson, MD, MS, MBA,Joshua D. Lenchus, DO, BSPharm,Jacqueline Glee Lenoir, PharmD,Claudette McPherson, RN, BSN,Jeffrey Nemeth, PharmD, MPA,Ralph J. Riello III, PharmD Adherence and Dosing Frequency of Common Medications for Cardiovascular Patients
ByJay P. Bae, PhD,Paul P. Dobesh, PharmD,Donald G. Klepser, PhD, MBA,Johnna D. Anderson, MS,Anthony J. Zagar, MS,Patrick L. McCollam, PharmD,Molly E. Tomlin, MS In this database analysis, greater adherence was observed for once-daily dosing compared with twice-daily dosing with chronic-use prescription medications used by patients with cardiovascular disease.